Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 9 Neoplasms 8 Prostatic Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Leukemia, Myeloid, Acute 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Small Cell Lung Carcinoma 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Prostate Cancer Metastatic 1 Primary Myelofibrosis 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Polycythemia Vera 1 Pathologic Complete Response 1 Osteosarcoma 1 Neuroendocrine Tumors 1

Interventions

pembrolizumab 37 Gemcitabine 29 Nivolumab 20 Cisplatin 19 atezolizumab 15 avelumab 14 Docetaxel 13 enfortumab vedotin 10 Carboplatin 10 durvalumab 9 Magnetic Resonance Spectroscopy 9 Ipilimumab 8 Paclitaxel 7 Pemetrexed 6 toripalimab 5 cabozantinib 5 Fluorodeoxyglucose F18 5 sacituzumab govitecan 4 cabazitaxel 4 Taxes 4 vinflunine 3 tremelimumab 3 pemigatinib 3 X-Rays 3 Standard of Care 3 Specimen Handling 3 Radiotherapy 3 Mitomycin 3 Immunotherapy 3 Immunoglobulin G 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Transitional Cell × talazoparib × Clear all

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡